{"PubmedArticleSet": {"PubmedArticle": {"MedlineCitation": {"@Status": "MEDLINE", "@Owner": "NLM", "@IndexingMethod": "Automated", "PMID": {"@Version": "1", "#text": "33248227"}, "DateCompleted": {"Year": "2021", "Month": "02", "Day": "08"}, "DateRevised": {"Year": "2022", "Month": "01", "Day": "29"}, "Article": {"@PubModel": "Print-Electronic", "Journal": {"ISSN": {"@IssnType": "Electronic", "#text": "1569-8041"}, "JournalIssue": {"@CitedMedium": "Internet", "Volume": "32", "Issue": "2", "PubDate": {"Year": "2021", "Month": "Feb"}}, "Title": "Annals of oncology : official journal of the European Society for Medical Oncology", "ISOAbbreviation": "Ann Oncol"}, "ArticleTitle": "Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.", "Pagination": {"StartPage": "183", "EndPage": "196", "MedlinePgn": "183-196"}, "ELocationID": [{"@EIdType": "doi", "@ValidYN": "Y", "#text": "10.1016/j.annonc.2020.11.013"}, {"@EIdType": "pii", "@ValidYN": "Y", "#text": "S0923-7534(20)43168-0"}], "Abstract": {"AbstractText": "This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of 'all-comer' treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.", "CopyrightInformation": "Copyright \u00a9 2020 The Authors. Published by Elsevier Ltd.. All rights reserved."}, "AuthorList": {"@CompleteYN": "Y", "Author": [{"@ValidYN": "Y", "LastName": "Casolino", "ForeName": "R", "Initials": "R", "AffiliationInfo": {"Affiliation": "Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK; Department of Medicine, University and Hospital Trust of Verona, Verona, Italy."}}, {"@ValidYN": "Y", "LastName": "Braconi", "ForeName": "C", "Initials": "C", "AffiliationInfo": {"Affiliation": "Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK."}}, {"@ValidYN": "Y", "LastName": "Malleo", "ForeName": "G", "Initials": "G", "AffiliationInfo": {"Affiliation": "Department of Surgery, University and Hospital Trust of Verona, Verona, Italy."}}, {"@ValidYN": "Y", "LastName": "Paiella", "ForeName": "S", "Initials": "S", "AffiliationInfo": {"Affiliation": "Department of Surgery, University and Hospital Trust of Verona, Verona, Italy."}}, {"@ValidYN": "Y", "LastName": "Bassi", "ForeName": "C", "Initials": "C", "AffiliationInfo": {"Affiliation": "Department of Surgery, University and Hospital Trust of Verona, Verona, Italy."}}, {"@ValidYN": "Y", "LastName": "Milella", "ForeName": "M", "Initials": "M", "AffiliationInfo": {"Affiliation": "Department of Medicine, Medical Oncology, University and Hospital Trust of Verona, Verona (VR), Italy."}}, {"@ValidYN": "Y", "LastName": "Dreyer", "ForeName": "S B", "Initials": "SB", "AffiliationInfo": {"Affiliation": "Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK."}}, {"@ValidYN": "Y", "LastName": "Froeling", "ForeName": "F E M", "Initials": "FEM", "AffiliationInfo": {"Affiliation": "Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, UK."}}, {"@ValidYN": "Y", "LastName": "Chang", "ForeName": "D K", "Initials": "DK", "AffiliationInfo": {"Affiliation": "Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK."}}, {"@ValidYN": "Y", "LastName": "Biankin", "ForeName": "A V", "Initials": "AV", "AffiliationInfo": {"Affiliation": "Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK; South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Liverpool, NSW, Australia. Electronic address: andrew.biankin@glasgow.ac.uk."}}, {"@ValidYN": "Y", "LastName": "Golan", "ForeName": "T", "Initials": "T", "AffiliationInfo": {"Affiliation": "Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel."}}]}, "Language": "eng", "GrantList": {"@CompleteYN": "Y", "Grant": [{"GrantID": "C29717/A18484", "Acronym": "CRUK_", "Agency": "Cancer Research UK", "Country": "United Kingdom"}, {"GrantID": "RIF2014_01_BRACONI", "Acronym": "PANCREATICCANUK_", "Agency": "Pancreatic Cancer UK", "Country": "United Kingdom"}, {"GrantID": "C29717/A17263", "Acronym": "CRUK_", "Agency": "Cancer Research UK", "Country": "United Kingdom"}, {"GrantID": "C596/A18076", "Acronym": "CRUK_", "Agency": "Cancer Research UK", "Country": "United Kingdom"}, {"GrantID": "103721/Z/14/Z", "Acronym": "WT_", "Agency": "Wellcome Trust", "Country": "United Kingdom"}, {"Acronym": "WT_", "Agency": "Wellcome Trust", "Country": "United Kingdom"}, {"GrantID": "C596/A20921", "Acronym": "CRUK_", "Agency": "Cancer Research UK", "Country": "United Kingdom"}]}, "PublicationTypeList": {"PublicationType": [{"@UI": "D016428", "#text": "Journal Article"}, {"@UI": "D013485", "#text": "Research Support, Non-U.S. Gov't"}, {"@UI": "D016454", "#text": "Review"}]}, "ArticleDate": {"@DateType": "Electronic", "Year": "2020", "Month": "11", "Day": "26"}}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Ann Oncol", "NlmUniqueID": "9007735", "ISSNLinking": "0923-7534"}, "ChemicalList": {"Chemical": {"RegistryNumber": "0", "NameOfSubstance": {"@UI": "D014408", "#text": "Biomarkers, Tumor"}}}, "CitationSubset": "IM", "MeshHeadingList": {"MeshHeading": [{"DescriptorName": {"@UI": "D014408", "@MajorTopicYN": "N", "#text": "Biomarkers, Tumor"}, "QualifierName": {"@UI": "Q000235", "@MajorTopicYN": "N", "#text": "genetics"}}, {"DescriptorName": {"@UI": "D006801", "@MajorTopicYN": "N", "#text": "Humans"}}, {"DescriptorName": {"@UI": "D020360", "@MajorTopicYN": "N", "#text": "Neoadjuvant Therapy"}}, {"DescriptorName": {"@UI": "D010190", "@MajorTopicYN": "Y", "#text": "Pancreatic Neoplasms"}, "QualifierName": {"@UI": "Q000601", "@MajorTopicYN": "N", "#text": "surgery"}}, {"DescriptorName": {"@UI": "D057285", "@MajorTopicYN": "Y", "#text": "Precision Medicine"}}, {"DescriptorName": {"@UI": "D011379", "@MajorTopicYN": "N", "#text": "Prognosis"}}]}, "KeywordList": {"@Owner": "NOTNLM", "Keyword": [{"@MajorTopicYN": "N", "#text": "Pancreatic cancer"}, {"@MajorTopicYN": "N", "#text": "neoadjuvant"}, {"@MajorTopicYN": "N", "#text": "precision medicine"}, {"@MajorTopicYN": "N", "#text": "predictive biomarkers"}, {"@MajorTopicYN": "N", "#text": "preoperative"}, {"@MajorTopicYN": "N", "#text": "prognostic biomarkers"}]}, "CoiStatement": "Disclosure The authors have declared no conflicts of interest."}, "PubmedData": {"History": {"PubMedPubDate": [{"@PubStatus": "received", "Year": "2020", "Month": "10", "Day": "9"}, {"@PubStatus": "revised", "Year": "2020", "Month": "11", "Day": "16"}, {"@PubStatus": "accepted", "Year": "2020", "Month": "11", "Day": "17"}, {"@PubStatus": "pubmed", "Year": "2020", "Month": "11", "Day": "29", "Hour": "6", "Minute": "0"}, {"@PubStatus": "medline", "Year": "2021", "Month": "2", "Day": "9", "Hour": "6", "Minute": "0"}, {"@PubStatus": "entrez", "Year": "2020", "Month": "11", "Day": "28", "Hour": "20", "Minute": "7"}]}, "PublicationStatus": "ppublish", "ArticleIdList": {"ArticleId": [{"@IdType": "pubmed", "#text": "33248227"}, {"@IdType": "pmc", "#text": "PMC7840891"}, {"@IdType": "doi", "#text": "10.1016/j.annonc.2020.11.013"}, {"@IdType": "pii", "#text": "S0923-7534(20)43168-0"}]}, "ReferenceList": {"Reference": [{"Citation": "Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "29313949"}}}, {"Citation": "Bray F., Ferlay J., Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30207593"}}}, {"Citation": "Gillen S., Schuster T., Meyer Zum Buschenfelde C. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC2857873"}, {"@IdType": "pubmed", "#text": "20422030"}]}}, {"Citation": "Oettle H., Neuhaus P., Hochhaus A. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473\u20131481.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "24104372"}}}, {"Citation": "Groot V.P., Daamen L.A., Hagendoorn J. Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma. J Surg Res. 2018;221:152\u2013160.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "29229122"}}}, {"Citation": "Strobel O., Neoptolemos J., Jager D., Buchler M.W. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16:11\u201326.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30341417"}}}, {"Citation": "Conroy T., Hammel P., Hebbar M. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u20132406.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30575490"}}}, {"Citation": "Liu X., Fu Y., Chen Q. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. BMC Gastroenterol. 2018;18:168.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6220565"}, {"@IdType": "pubmed", "#text": "30400836"}]}}, {"Citation": "Versteijne E., Suker M., Groothuis K. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763\u20131773.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "32105518"}}}, {"Citation": "Mayo S.C., Gilson M.M., Herman J.M. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214:33\u201345.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC3578342"}, {"@IdType": "pubmed", "#text": "22055585"}]}}, {"Citation": "Merkow R.P., Bilimoria K.Y., Tomlinson J.S. Post-operative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260:372\u2013377.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "24374509"}}}, {"Citation": "Valle J.W., Palmer D., Jackson R. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504\u2013512.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "24419109"}}}, {"Citation": "Jang J.Y., Han Y., Lee H. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268:215\u2013222.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "29462005"}}}, {"Citation": "Maggino L., Malleo G., Marchegiani G. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154(10):932\u2013942.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6659151"}, {"@IdType": "pubmed", "#text": "31339530"}]}}, {"Citation": "Lee Y.S., Lee J.C., Yang S.Y. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: a systematic review and meta-analysis. Sci Rep. 2019;9:15662.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6821820"}, {"@IdType": "pubmed", "#text": "31666626"}]}}, {"Citation": "Bradley A., Van Der Meer R. Upfront Surgery versus neoadjuvant therapy for resectable pancreatic cancer: systematic review and bayesian network meta-analysis. Sci Rep. 2019;9:4354.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6416273"}, {"@IdType": "pubmed", "#text": "30867522"}]}}, {"Citation": "Chawla A., Ferrone C.R. Neoadjuvant therapy for resectable pancreatic cancer: an evolving paradigm shift. Front Oncol. 2019;9:1085.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6811513"}, {"@IdType": "pubmed", "#text": "31681614"}]}}, {"Citation": "Mokdad A.A., Minter R.M., Zhu H. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35:515\u2013522.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "27621388"}}}, {"Citation": "Roland C.L., Yang A.D., Katz M.H. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168\u20131175.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5131370"}, {"@IdType": "pubmed", "#text": "25352267"}]}}, {"Citation": "Laurence J.M., Tran P.D., Morarji K. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011;15:2059\u20132069.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "21913045"}}}, {"Citation": "Ye M., Zhang Q., Chen Y. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. HPB (Oxford) 2020;22:821\u2013832.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "32001139"}}}, {"Citation": "Janssen Q.P., O'Reilly E.M., van Eijck C.H.J., Groot Koerkamp B. Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer. Front Oncol. 2020;10:41.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7005204"}, {"@IdType": "pubmed", "#text": "32083002"}]}}, {"Citation": "Kulkarni N.M., Soloff E.V., Tolat P.P. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdom Radiol (NY) 2020;45:716\u2013728.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31748823"}}}, {"Citation": "Oba A., Ho F., Bao Q.R. Neoadjuvant treatment in pancreatic cancer. Front Oncol. 2020;10:245.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7058791"}, {"@IdType": "pubmed", "#text": "32185128"}]}}, {"Citation": "Ferrone C.R., Marchegiani G., Hong T.S. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261:12\u201317.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4349683"}, {"@IdType": "pubmed", "#text": "25599322"}]}}, {"Citation": "Varadhachary G.R., Tamm E.P., Abbruzzese J.L. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035\u20131046.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "16865597"}}}, {"Citation": "Dixon E., Abdalla E., Schwarz R.E., Vauthey J.N. AHPBA/SSO/SSAT sponsored consensus conference on multidisciplinary treatment of hepatocellular carcinoma. HPB (Oxford) 2010;12:287\u2013288.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC2951813"}, {"@IdType": "pubmed", "#text": "20590900"}]}}, {"Citation": "Katz M.H., Marsh R., Herman J.M. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20:2787\u20132795.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5600517"}, {"@IdType": "pubmed", "#text": "23435609"}]}}, {"Citation": "Bockhorn M., Uzunoglu F.G., Adham M. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS) Surgery. 2014;155:977\u2013988.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "24856119"}}}, {"Citation": "Isaji S., Mizuno S., Windsor J.A. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2\u201311.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "29191513"}}}, {"Citation": "Tempero M.A. NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw. 2019;17:603\u2013605.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31117041"}}}, {"Citation": "Tang K., Lu W., Qin W., Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016;16:28\u201337.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "26687001"}}}, {"Citation": "Janssen Q.P., Buettner S., Suker M. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782\u2013794.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6695305"}, {"@IdType": "pubmed", "#text": "31086963"}]}}, {"Citation": "Versteijne E., Suker M., Groothuis K. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38:1763\u20131773.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "32105518"}}}, {"Citation": "Xu C.P., Xue X.J., Liang N. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140:549\u2013559.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "24370686"}}}, {"Citation": "Suker M., Beumer B.R., Sadot E. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801\u2013810.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5527756"}, {"@IdType": "pubmed", "#text": "27160474"}]}}, {"Citation": "Kleeff J., Ronellenfitsch U., Michalski C.W. Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer? EClinicalMedicine. 2019;17:100222.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6933141"}, {"@IdType": "pubmed", "#text": "31891149"}]}}, {"Citation": "Jung J., Yoon S.M., Park J.H. Stereotactic body radiation therapy for locally advanced pancreatic cancer. PLoS One. 2019;14:e0214970.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6461258"}, {"@IdType": "pubmed", "#text": "30978229"}]}}, {"Citation": "Tempero M.A., Malafa M.P., Chiorean E.G. Pancreatic adenocarcinoma, version 1.2019. J Natl Compr Canc Netw. 2019;17:202\u2013210.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30865919"}}}, {"Citation": "Pentheroudakis G., Committee E.G. Recent eupdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer. Ann Oncol. 2019;30:1395\u20131397.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31168599"}}}, {"Citation": "Khorana A.A., McKernin S.E., Berlin J. Potentially curable pancreatic adenocarcinoma: ASCO Clinical Practice Guideline update. J Clin Oncol. 2019;37:2082\u20132088.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31180816"}}}, {"Citation": "Gulhati P., Prakash L., Katz M.H.G. First-line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26:619\u2013627.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30324485"}}}, {"Citation": "Paiella S., De Pastena M., Romeo F. Ablation treatments in unresectable pancreatic cancer. Minerva Chir. 2019;74:263\u2013269.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30600963"}}}, {"Citation": "Ducreux M., Cuhna A.S., Caramella C. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v56\u2013v68.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "26314780"}}}, {"Citation": "Pan L., Fang J., Tong C. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;18:1.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6937851"}, {"@IdType": "pubmed", "#text": "31892339"}]}}, {"Citation": "Reni M., Balzano G., Zanon S. Safety and efficacy of preoperative or post-operative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018;3:413\u2013423.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "29625841"}}}, {"Citation": "Ghaneh P., Palmer D.H., Cicconi S. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol. 2020;38:4505."}, {"Citation": "Sohal D., Duong M.T., Ahmad S.A. SWOG S1505: results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA) J Clin Oncol. 2020;38:4504."}, {"Citation": "Gilbert J.W., Wolpin B., Clancy T. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol. 2017;28:2067\u20132076.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5834155"}, {"@IdType": "pubmed", "#text": "28407088"}]}}, {"Citation": "Heinrich S., Besselink M., Moehler M. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer. 2019;19:675.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6617881"}, {"@IdType": "pubmed", "#text": "31288786"}]}}, {"Citation": "Dreyer S.B., Chang D.K., Bailey P., Biankin A.V. Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clin Cancer Res. 2017;23:1638\u20131646.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "28373362"}}}, {"Citation": "Biankin A.V., Waddell N., Kassahn K.S. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399\u2013405.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC3530898"}, {"@IdType": "pubmed", "#text": "23103869"}]}}, {"Citation": "Waddell N., Pajic M., Patch A.M. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495\u2013501.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4523082"}, {"@IdType": "pubmed", "#text": "25719666"}]}}, {"Citation": "Bailey P., Chang D.K., Nones K. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47\u201352.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "26909576"}}}, {"Citation": "Pishvaian M.J., Blais E.M., Brody J.R. Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumour program. JCO Precision Oncology. 2019;3:1\u201310."}, {"Citation": "Aguirre A.J., Nowak J.A., Camarda N.D. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov. 2018;8:1096\u20131111.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6192263"}, {"@IdType": "pubmed", "#text": "29903880"}]}}, {"Citation": "Aung K.L., Fischer S.E., Denroche R.E. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24:1344\u20131354.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5968824"}, {"@IdType": "pubmed", "#text": "29288237"}]}}, {"Citation": "Park W., Chen J., Chou J.F. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26:3239\u20133247.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7380542"}, {"@IdType": "pubmed", "#text": "32444418"}]}}, {"Citation": "Golan T., Varadhachary G.R., Sela T. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J Clin Oncol. 2018;36:297."}, {"Citation": "Zhu H., Wei M., Xu J. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020;19:49.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7053129"}, {"@IdType": "pubmed", "#text": "32122376"}]}}, {"Citation": "Golan T., Hammel P., Reni M. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u2013327.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6810605"}, {"@IdType": "pubmed", "#text": "31157963"}]}}, {"Citation": "Sahin I.H., Askan G., Hu Z.I., O'Reilly E.M. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? Ann Oncol. 2017;28:2950\u20132961.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5834032"}, {"@IdType": "pubmed", "#text": "28945842"}]}}, {"Citation": "Martens S., Lefesvre P., Nicolle R. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Ann Oncol. 2019;30:1428\u20131436.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31161208"}}}, {"Citation": "Collisson E.A., Bailey P., Chang D.K., Biankin A.V. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16:207\u2013220.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30718832"}}}, {"Citation": "Collisson E.A., Sadanandam A., Olson P. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500\u2013503.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC3755490"}, {"@IdType": "pubmed", "#text": "21460848"}]}}, {"Citation": "Nagtegaal I.D., Odze R.D., Klimstra D. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u2013188.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7003895"}, {"@IdType": "pubmed", "#text": "31433515"}]}}, {"Citation": "Moffitt R.A., Marayati R., Flate E.L. Virtual microdissection identifies distinct tumour- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168\u20131178.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4912058"}, {"@IdType": "pubmed", "#text": "26343385"}]}}, {"Citation": "Hoadley K.A., Yau C., Wolf D.M. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158:929\u2013944.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4152462"}, {"@IdType": "pubmed", "#text": "25109877"}]}}, {"Citation": "Martinelli P., Carrillo-de Santa Pau E., Cox T. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut. 2017;66:1665\u20131676.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5070637"}, {"@IdType": "pubmed", "#text": "27325420"}]}}, {"Citation": "O'Kane G.M., Grunwald B.T., Jang G.H. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res. 2020;26(18):4901\u20134910.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "32156747"}}}, {"Citation": "Martinelli P., Carrillo-de Santa Pau E., Cox T. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut. 2017;66:1665\u20131676.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5070637"}, {"@IdType": "pubmed", "#text": "27325420"}]}}, {"Citation": "Dreyer S.B., Pinese M., Jamieson N.B. Precision oncology in surgery: patient selection for operable pancreatic cancer. Ann Surg. 2020;272:366\u2013376.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7373491"}, {"@IdType": "pubmed", "#text": "32675551"}]}}, {"Citation": "Dreyer S.B., Jamieson N.B., Morton J.P. Pancreatic cancer: from genome discovery to PRECISION-Panc. Clin Oncol (R Coll Radiol) 2020;32:5\u20138.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31522943"}}}, {"Citation": "Murphy J.E., Wo J.Y., Ryan D.P. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4:963\u2013969.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6145728"}, {"@IdType": "pubmed", "#text": "29800971"}]}}, {"Citation": "He J., Blair A.B., Groot V.P. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg. 2018;268:1\u20138.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6178802"}, {"@IdType": "pubmed", "#text": "29334562"}]}}, {"Citation": "Gemenetzis G., Groot V.P., Blair A.B. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270:340\u2013347.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6985003"}, {"@IdType": "pubmed", "#text": "29596120"}]}}, {"Citation": "Motoi F., Kosuge T., Ueno H. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05) Jpn J Clin Oncol. 2019;49:190\u2013194.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30608598"}}}, {"Citation": "Zhao Q., Rashid A., Gong Y. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16:29\u201337.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC3832988"}, {"@IdType": "pubmed", "#text": "22050964"}]}}, {"Citation": "Khattab A., Patruni S., Abel S. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma. J Gastrointest Oncol. 2019;10:918\u2013927.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6776797"}, {"@IdType": "pubmed", "#text": "31602330"}]}}, {"Citation": "Townend P., de Reuver P.R., Chua T.C. Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data. ANZ J Surg. 2018;88:E167\u2013E172.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "28318082"}}}, {"Citation": "Golan T., Barenboim A., Lahat G. Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer. Ann Surg Oncol. 2020;27:3963\u20133970.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "32314163"}}}, {"Citation": "He J., Blair A.B., Groot V.P. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg. 2018;268(1):1\u20138.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6178802"}, {"@IdType": "pubmed", "#text": "29334562"}]}}, {"Citation": "Patil S., Steuber B., Kopp W. EZH2 regulates pancreatic cancer subtype identity and tumour progression via transcriptional repression of GATA6. Cancer Res. 2020;80(21):4620\u20134632.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "32907838"}}}, {"Citation": "Chang D.K., Grimmond S.M., Evans T.R., Biankin A.V. Mining the genomes of exceptional responders. Nat Rev Cancer. 2014;14:291\u2013292.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "25688402"}}}, {"Citation": "Rombouts S.J., Walma M.S., Vogel J.A. Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol. 2016;23:4352\u20134360.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5090009"}, {"@IdType": "pubmed", "#text": "27370653"}]}}, {"Citation": "Park W., Wong W., Yu K.H. Homologous recombination deficiency (HRD): a biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC) J Clin Oncol. 2019;37:4132."}, {"Citation": "Torgeson A., Lloyd S., Boothe D. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer. 2017;123:3816\u20133824.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "28621885"}}}, {"Citation": "Nevala-Plagemann C., Hidalgo M., Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17:108\u2013123.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31705130"}}}, {"Citation": "Berger M.F., Mardis E.R. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15:353\u2013365.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6658089"}, {"@IdType": "pubmed", "#text": "29599476"}]}}, {"Citation": "Ersek J.L., Black L.J., Thompson M.A., Kim E.S. Implementing precision medicine programs and clinical trials in the community-based oncology practice: barriers and best practices. Am Soc Clin Oncol Educ Book. 2018;38:188\u2013196.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30231363"}}}, {"Citation": "Kitano M., Yoshida T., Itonaga M. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J Gastroenterol. 2019;54:19\u201332.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6314985"}, {"@IdType": "pubmed", "#text": "30406288"}]}}, {"Citation": "Baek H.W., Park M.J., Rhee Y.Y. Diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology of pancreatic lesions. J Pathol Transl Med. 2015;49:52\u201360.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4357401"}, {"@IdType": "pubmed", "#text": "25812658"}]}}, {"Citation": "Cros J., Raffenne J., Couvelard A., Pote N. Tumour heterogeneity in pancreatic adenocarcinoma. Pathobiology. 2018;85:64\u201371.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "28787741"}}}, {"Citation": "Vietsch E.E., Graham G.T., McCutcheon J.N. Reprint of: circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genet. 2018;228-229:131\u2013142.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30447903"}}}, {"Citation": "Ahola R., Sand J., Laukkarinen J. Centralization of pancreatic surgery improves results: review. Scand J Surg. 2020;109:4\u201310.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31969066"}}}, {"Citation": "Balzano G., Guarneri G., Pecorelli N. Modelling centralization of pancreatic surgery in a nationwide analysis. Br J Surg. 2020;107:1510\u20131519.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "32592514"}}}, {"Citation": "Dreyer S.B., Jamieson N.B., Cooke S.L. PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clin Oncol (R Coll Radiol) 2020;32:1\u20134.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31378449"}}}, {"Citation": "Dreyer S.B., Jamieson N.B., Evers L. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chin Clin Oncol. 2019;8:16.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31070037"}}}, {"Citation": "Lowery M.A., Jordan E.J., Basturk O. Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res. 2017;23:6094\u20136100.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "28754816"}}}, {"Citation": "Chantrill L.A., Nagrial A.M., Watson C. Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res. 2015;21:2029\u20132037.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "25896973"}}}, {"Citation": "Lee M., Jones M.R., Williamson L. Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations. J Clin Oncol. 2019;37:e15753."}, {"Citation": "Marchegiani G., Andrianello S., Perri G. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma? HPB (Oxford) 2018;20:411\u2013417.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "29191689"}}}, {"Citation": "Kirkegard J., Mortensen F.V., Hansen C.P. Waiting time to surgery and pancreatic cancer survival: a nationwide population-based cohort study. Eur J Surg Oncol. 2019;45:1901\u20131905.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "31160135"}}}, {"Citation": "Mirkin K.A., Hollenbeak C.S., Wong J. Time to surgery: a misguided quality metric in early stage pancreatic cancer. J Gastrointest Surg. 2018;22:1365\u20131375.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "29520648"}}}, {"Citation": "Yu S., Agarwal P., Mamtani R. Retrospective survival analysis of patients with resected pancreatic ductal adenocarcinoma and a germline BRCA or PALB2 mutation. JCO Precision Oncology. 2019;3:1\u201311."}, {"Citation": "Dreyer S.B., Upstill-Goddard R., Paulus-Hock V. Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology. 2021;160(1):362\u2013377.e13.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8167930"}, {"@IdType": "pubmed", "#text": "33039466"}]}}, {"Citation": "Kocher H.M., Basu B., Froeling F.E.M. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun. 2020;11:4841.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7518421"}, {"@IdType": "pubmed", "#text": "32973176"}]}}, {"Citation": "Tuli R., Surmak A.J., Reyes J. Radiosensitization of pancreatic cancer cells in vitro and in vivo through poly (ADP-ribose) polymerase inhibition with ABT-888. Transl Oncol. 2014;7(3):439\u2013445.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4145354"}, {"@IdType": "pubmed", "#text": "24836647"}]}}, {"Citation": "Tuli R., Shiao S.L., Nissen N. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine. 2019;40:375\u2013381.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6412162"}, {"@IdType": "pubmed", "#text": "30635165"}]}}]}}}}}